The Congenital Heart Disease Priority Setting Partnership is bringing together parents, adult patients, charities, and clinicians from across both the spectrum of congenital heart disease and the UK to identify priorities for research. It is a collaboration between the Children’s Heart Federation, The Somerville Foundation, the British Congenital Cardiac Association, and the Society for Cardiothoracic Surgery, and is being hosted by the Institute for Cardiovascular Sciences at the University of Birmingham. It is funded by George Davies, the high street fashion entrepreneur behind brands such as Next, Per Una, and George at Asda, through a generous donation to the Birmingham Children’s Hospital Charity from the George Davies Charitable Trust.
The scope of this PSP is focused on the management of congenital heart disease throughout life, including prior to birth, in three areas of the patient and families experience:
- Diagnosis, during pregnancy or after birth.
- Treatment: medical therapy, catheter intervention, surgery including mechanical support & transplantation, lifestyle, or psychosocial intervention.
- Outcomes of the conditions and/or treatments and the impact on patients and their families, including the physical, psychological, and social effects of living with congenital heart disease.
We are not looking at areas which fall outside of these, such as the causes of congenital heart defects, acquired heart disease in those without a congenital heart defect, or aspects of congenital disorders that do not affect the heart.
The survey is now open and can be completed online or is available to download as a PDF in English, Welsh, Polish, Bengali, Urdu, Gujarati, and Hindi.
You can find out what we do with your data in our Privacy Notice.
This PSP will generate two Top 10 lists, one fetal/paediatric and one adult. These will be key in developing a national strategy for congenital heart disease research to address the issues which matter most, and will guide the scope and design of future clinical trials aimed at improving the clinical care and day-to-day lives of children and adults born with congenital heart disease.